FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128392790> ?p ?o ?g. }

• W3128392790 abstract "Endometrial cancer is the most frequent type of gynecological tumor in the United States. Hysterectomy, the surgical removal of the uterus, is the main therapy for endometrial cancer, but this is not an option for women seeking to preserve their fertility. In cases of early-stage endometrial cancer and endometrial hyperplasia, hormonal therapy is a vital nonsurgical option. However, progesterone (P4) resistance robs women of the option to choose hormone therapy to preserve their uterus. Therefore, developing nonsurgical treatments for endometrial cancer remains an essential goal for women who wish to maintain endometrial functions and women in high-risk surgical conditions. Mitogen-inducible gene 6 (MIG-6) acts as a tumor suppressor during endometrial tumorigenesis and as a P4 target gene in humans and mice. We developed mice with the conditional knockout of Mig-6 in all uterine compartments (Pgrcre/+Mig-6f/f; Mig-6KO) and endometrial epithelial cell-specific Mig-6 knockout (Sprr2fcre/+Mig-6f/f; Mig-6Ep-KO) mice. P4 treatment abated the development of endometrial hyperplasia and restored morphological and histological characteristics of the uterus of Mig-6Ep-KO mice, but Mig-6Ep-KO mice showed P4 resistance. P4 treatment reduced cell proliferation which was accompanied by decreased AKT signaling. In order to investigate the inhibition effect of AKT/mTOR signaling as non-surgical treatment on P4-resistant endometrial hyperplasia, we treated Mig-6KO and Mig-6Ep-KO mice with either: 1) vehicle (PBS); 2) MK-2206 (360 mg/kg, once a week); or 3) everolimus (10mg/kg daily) at 10 weeks old (n=6/treatment/genotype) for 1 month. MK-2206 has completed phase II trials and inhibits AKT phosphorylation. Everolimus is FDA-approved mTOR inhibitor. The vehicle group of Mig-6KO and Mig-6Ep-KO mice manifested the endometrial hyperplasia phenotype. In contrast, IHC analysis showed that the groups receiving MK-2206 or everolimus experienced significantly decreased AKT phosphorylation and phosphorylated S6 levels, respectively, and decreased epithelial proliferation, resulting in restoration of normal uterine histology. These data suggest that everolimus and MK-2206 may be new non-surgical treatment options for P4-resistant endometrial hyperplasia. This information may help guide more effective non-surgical interventions in the future. The project described was supported by Grant Number P50CA098258 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.Citation Format: Tae Hoon Kim, Jae-Wook Jeong. Everolimus and MK-2206 reverse P4-resistant endometrial hyperplasia in Mig-6 mutant mice [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr PO041." @default.
• W3128392790 created "2021-02-15" @default.
• W3128392790 creator A5041455638 @default.
• W3128392790 creator A5060789409 @default.
• W3128392790 date "2021-02-01" @default.
• W3128392790 modified "2023-09-27" @default.
• W3128392790 title "Abstract PO041: Everolimus and MK-2206 reverse P4-resistant endometrial hyperplasia in Mig-6 mutant mice" @default.
• W3128392790 doi "https://doi.org/10.1158/1557-3265.endomet20-po041" @default.
• W3128392790 hasPublicationYear "2021" @default.
• W3128392790 type Work @default.
• W3128392790 sameAs 3128392790 @default.
• W3128392790 citedByCount "0" @default.
• W3128392790 crossrefType "proceedings-article" @default.
• W3128392790 hasAuthorship W3128392790A5041455638 @default.
• W3128392790 hasAuthorship W3128392790A5060789409 @default.
• W3128392790 hasConcept C104317684 @default.
• W3128392790 hasConcept C121608353 @default.
• W3128392790 hasConcept C126322002 @default.
• W3128392790 hasConcept C127716648 @default.
• W3128392790 hasConcept C134018914 @default.
• W3128392790 hasConcept C142724271 @default.
• W3128392790 hasConcept C164659718 @default.
• W3128392790 hasConcept C2777088508 @default.
• W3128392790 hasConcept C2777562237 @default.
• W3128392790 hasConcept C2777689261 @default.
• W3128392790 hasConcept C2779066055 @default.
• W3128392790 hasConcept C2779494336 @default.
• W3128392790 hasConcept C2779699572 @default.
• W3128392790 hasConcept C502942594 @default.
• W3128392790 hasConcept C55493867 @default.
• W3128392790 hasConcept C62478195 @default.
• W3128392790 hasConcept C71924100 @default.
• W3128392790 hasConcept C75217442 @default.
• W3128392790 hasConcept C86554907 @default.
• W3128392790 hasConcept C86803240 @default.
• W3128392790 hasConceptScore W3128392790C104317684 @default.
• W3128392790 hasConceptScore W3128392790C121608353 @default.
• W3128392790 hasConceptScore W3128392790C126322002 @default.
• W3128392790 hasConceptScore W3128392790C127716648 @default.
• W3128392790 hasConceptScore W3128392790C134018914 @default.
• W3128392790 hasConceptScore W3128392790C142724271 @default.
• W3128392790 hasConceptScore W3128392790C164659718 @default.
• W3128392790 hasConceptScore W3128392790C2777088508 @default.
• W3128392790 hasConceptScore W3128392790C2777562237 @default.
• W3128392790 hasConceptScore W3128392790C2777689261 @default.
• W3128392790 hasConceptScore W3128392790C2779066055 @default.
• W3128392790 hasConceptScore W3128392790C2779494336 @default.
• W3128392790 hasConceptScore W3128392790C2779699572 @default.
• W3128392790 hasConceptScore W3128392790C502942594 @default.
• W3128392790 hasConceptScore W3128392790C55493867 @default.
• W3128392790 hasConceptScore W3128392790C62478195 @default.
• W3128392790 hasConceptScore W3128392790C71924100 @default.
• W3128392790 hasConceptScore W3128392790C75217442 @default.
• W3128392790 hasConceptScore W3128392790C86554907 @default.
• W3128392790 hasConceptScore W3128392790C86803240 @default.
• W3128392790 hasLocation W31283927901 @default.
• W3128392790 hasOpenAccess W3128392790 @default.
• W3128392790 hasPrimaryLocation W31283927901 @default.
• W3128392790 hasRelatedWork W2064116264 @default.
• W3128392790 hasRelatedWork W2069197273 @default.
• W3128392790 hasRelatedWork W2174432297 @default.
• W3128392790 hasRelatedWork W2395547044 @default.
• W3128392790 hasRelatedWork W2409106068 @default.
• W3128392790 hasRelatedWork W2557495611 @default.
• W3128392790 hasRelatedWork W2772286407 @default.
• W3128392790 hasRelatedWork W2945977427 @default.
• W3128392790 hasRelatedWork W3100569309 @default.
• W3128392790 hasRelatedWork W4312999812 @default.
• W3128392790 isParatext "false" @default.
• W3128392790 isRetracted "false" @default.
• W3128392790 magId "3128392790" @default.
• W3128392790 workType "article" @default.